Goldstein Advisors LLC Lowers Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Goldstein Advisors LLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 9.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,974 shares of the medical research company’s stock after selling 213 shares during the period. Goldstein Advisors LLC’s holdings in Natera were worth $312,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NTRA. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after buying an additional 469,327 shares during the last quarter. PointState Capital LP grew its stake in shares of Natera by 112.0% during the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock valued at $99,343,000 after buying an additional 413,468 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Natera by 53.6% during the second quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company’s stock valued at $103,783,000 after buying an additional 334,630 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Natera by 42.6% during the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock valued at $144,958,000 after buying an additional 328,375 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, Director Gail Boxer Marcus sold 2,212 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the transaction, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. The trade was a 10.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rowan E. Chapman sold 1,767 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total transaction of $300,814.08. Following the completion of the transaction, the director now owns 6,202 shares of the company’s stock, valued at approximately $1,055,828.48. The trade was a 22.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 224,824 shares of company stock worth $36,912,749. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Robert W. Baird raised their price objective on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. TD Cowen raised their price objective on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Canaccord Genuity Group raised their target price on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.94.

Natera Stock Performance

Natera stock opened at $171.93 on Thursday. The stock’s 50 day simple moving average is $165.35 and its two-hundred day simple moving average is $135.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market cap of $22.70 billion, a price-to-earnings ratio of -97.69 and a beta of 1.65. Natera, Inc. has a fifty-two week low of $62.96 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the business earned ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis. As a group, analysts expect that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.